NVTRQ Nuvectra

Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019

Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019

PLANO, Texas, July 17, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019 after market close.

Nuvectra will hold a conference call on Wednesday, July 31, 2019 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 3264026.  A live webcast of the conference call will be available on the investor relations section of the Company’s website at .

A replay of the call will be available starting on July 31, 2019 through August 7, 2019. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 3264026. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.

About Nuvectra Corporation

Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. Visit the Nuvectra website at .

Company Contacts:           

Nuvectra Corporation         



Jennifer Kosharek                 

(214) 474-3107                     

Investor Contact:

The Ruth Group



Tram Bui

(646) 536-7035     

EN
17/07/2019

Underlying

NVTRQNuvectra

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nuvectra

 PRESS RELEASE
Free
NVTRQ NUVECTRA

Nuvectra® Continuing to Support Current Patients with the Algovita® ...

Nuvectra® Continuing to Support Current Patients with the Algovita® Implant as Company Voluntarily Files for Chapter 11 Court-Supervised Process Has No Impact on Safety or Functionality of Algovita Device; Company Continuing to Support Physicians PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR) (“Nuvectra” or the “Company”), a neurostimulation medical device company, today announced that it has elected to file a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern Distr...

November 12, 2019 1 EN
 PRESS RELEASE
Free
NVTRQ NUVECTRA

Nuvectra Submits Chemical Composition and Biocompatibility Data to FDA...

Nuvectra Submits Chemical Composition and Biocompatibility Data to FDA for Virtis™  PLANO, Texas, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced it has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration (FDA) in support of the Company’s Virtis pre-market approval (PMA) application for the treatment of chronic urinary retention and symptoms of overactive bladder. Fred Parks, Chief Executive Officer, commented, “In April of this year, the FDA reque...

October 18, 2019 1 EN
 PRESS RELEASE
Free
NVTRQ NUVECTRA

Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer

Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer PLANO, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Jennifer Kosharek as Chief Financial Officer, effective September 16, 2019. Ms. Kosharek will assume the role of Chief Financial Officer after having served as the Company’s interim Chief Financial Officer since May 2019, leveraging over fifteen years of audit and accounting experience and various finance and leadership positions within Nuvectra. Dr. Fred Parks, ...

September 20, 2019 1 EN
 PRESS RELEASE
Free
NVTRQ NUVECTRA

Nuvectra® Exploring Strategic Options to Enhance Shareholder Value

Nuvectra® Exploring Strategic Options to Enhance Shareholder Value PLANO, Texas, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance shareholder value. The Company is currently evaluating all options, including a sale or merger of the Company, to finance the expected growth of the Nuvectra business. Anthony Bihl, Chairman of the Board, commented, "We are thankful to our employees for their hard work in support of ou...

August 26, 2019 1 EN
 PRESS RELEASE
Free
NVTRQ NUVECTRA

Nuvectra® Reports Second Quarter 2019 Financial Results

Nuvectra® Reports Second Quarter 2019 Financial Results PLANO, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended June 30, 2019. Recent Business Highlights Algovita® revenues increased 7% year-over-year to $12.3 millionFiled regulatory submission with FDA for Algovita full-body MR conditional approvalHighlighted positive preliminary Algovita clinical data at the INS 14th Annual World CongressRevised full year 2019 Algovita revenue guidance to $50-55 millio...

July 31, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch